Willis M. Wu, M.D.
Dr. Wu joined North Carolina Heart & Vascular in 2013 after completing fellowship training at the Cleveland Clinic. Since 2013, he has specialized in complex coronary interventions and structural heart interventions which include transcatheter aortic valve replacement, percutaneous mitral valve repair, percutaneous left atrial appendage occlusion, and percutaneous closure of patent foramen ovale/atrial septal defects. In addition, he has helped run clinical trials investigating percutaneous valve interventions and new coronary techniques. He now serves as the Director of the Structural Heart program at UNC REX Healthcare.
- Spending time with family
- Exercise, including running, biking, swimming
- Collegiate lacrosse
FELLOWSHIP & POSTGRADUATE TRAINING
- Fellowship, Interventional Cardiology, Cleveland Clinic, Cleveland, OH
- Fellowship, Cardiovascular Medicine, Chief Fellow, Cleveland Clinic, Cleveland, OH
- Chief Fellow, Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH
- Residency: Internal Medicine, Chief Resident, University of North Carolina Hospitals, Chapel Hill, NC
- Chief Resident, Internal Medicine, University of North Carolina Hospitals, Chapel Hill, NC
- Medical Degree: University of Maryland School of Medicine, Baltimore, MD
- Undergraduate Degree: Princeton University, Princeton, NJ
- Internal Medicine 2007
- Cardiovascular Medicine 2011
- Interventional Cardiology 2012
- Registered Physician in Vascular Interpretation 2013
- Fellow of the American College of Cardiology
- American Registry for Diagnostic Medical Sonography
- Coronary Intervention (Complex angioplasty, atherectomy, and stenting techniques including intervention of chronic total occlusions)
- Peripheral Vascular Intervention (Carotid angiography, upper and lower extremity angioplasty, atherectomy, and stenting, renal and mesenteric artery intervention)
- Cardiac Structural Intervention (Transcatheter Aortic Valve Replacement, balloon aortic valvuloplasty, Atrial Septal Defect and Patent Foramen Ovale closure, paravalvular leak closure, mitral valve intervention)
- Wu W, Masri A, Popovic ZB, Smedira NG, Lytle BW, Marwick TH,
Griffin BP, Desai MY. “Long-term survival of patients with radiation
heart disease undergoing cardiac surgery: a cohort study.” Circulation.
2013 Apr 9;127(14):1476-84.
- Wu W, Lincoff AM. “Pharmacotherapy During Saphenous Vein Graft
Intervention.” Intervent Cardiol Clin 2 2013: 273-282.
- Khurana RK, Wu WM, “The Valsalva Maneuver: A Literature Review and
Personal Observations”, Autonomic Review, 2001, Volume: 5, Pages: 61-70.
- Wu W, Runge M. “Sudden Cardiac Death in Athletes.” In: Runge, Patterson,
Stouffer editors. Netter’s Cardiology 2nd Edition. Philadelphia, PA: Saunders
- Wu W, Kapadia S. “Risk Stratification and Post-Myocardial Infarction Therapy”
In: Griffin, Kapadia, Rimmerman editors. The Cleveland Clinic Cardiology
Board Review 2nd Edition. Philadelphia, PA: Lippincott. 2013: 627-640.
- Wu W, Menon V. “Post-Myocardial Infarction Risk Stratification and
Management.” In: Griffin, editor. Manual of Cardiovascular Medicine 4th
Edition. Philadelphia, PA: Lippincott. 2013: 86-96.
- “The role of percutaneous mitral repair for high risk patients” in Percutaneous
Mitral Leaflet Repair: MitraClip Therapy for Mitral Regurgitation. 2013.
- Wu W, Smedira N, Hammer D, Marwick T, Lytle B, Griffin B, Desai M.
“Long-term outcomes of patients with radiation heart disease undergoing cardiac
surgery: Clinical and Echocardiographic predictors” Presented at ACC 2011.
- Ko C, Kim S, Wu WM, Chua SC, Jr., Huang L-S, “A Quantitative Trait Locus
(QTL) on Chromosome 5 is Associated with Plasma ApoB responsiveness to
Fish Oil in Human ApoB Transgenic Mouse Strains”, Supplement to American
Journal of Human Genetics, 2001, Volume: 69, Page 525.